GTC
SAGE

Ghost Tree Capital’s Sage Therapeutics SAGE Stock Holding History

Ghost Tree Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-43,700
Closed -$7.2M – 64
2017
Q4 		$7.2M Sell
43,700
-106,300
-71% -$10.3M 1.69% 22
2017
Q3 		$9.35M Buy
+150,000
New +$11.8M 1.98% 18

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ghost Tree Capital's SAGE Position: Q2 2021 in Review

Ghost Tree Capital sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 30,000 shares — an estimated $2.25M sold.

Ghost Tree Capital first reported a position in SAGE in Q1 2015 and held it in 18 quarters. The position peaked at $15.4M in Q3 2019. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Ghost Tree Capital reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ghost Tree Capital sold 30,000 Sage Therapeutics shares in Q2 2021, an estimated $2.25M.
  • Ghost Tree Capital first reported a position in Sage Therapeutics in Q1 2015 and held it in 18 quarters.
  • Ghost Tree Capital's Sage Therapeutics position peaked at $15.4M in Q3 2019.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Ghost Tree Capital's 13F filing for Q2 2021, filed 11 Aug 2021.